Pharmaceutical Scientists To Meet In Boston

August 25, 1997

ALEXANDRIA, Va - (August 5, 1997) -- More than 5,000 pharmaceutical scientists will gather in Boston, Massachusetts, November 2 - 6, 1997, for the Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists (AAPS).

This year's theme, Revolutions in Pharmaceutical Research, is especially timely in an era where scientists are making significant strides in managing chronic diseases with drugs. More than 2,000 scientists will be presenting contributed papers on a variety of topics and issues. Other program offerings include symposia on "Lipid-Based Systems for Oral Drug Delivery," "Batch Failure Investigations" and "Pulmonary Delivery of Biopharmaceuticals."

The AAPS Annual Meeting provides an ideal venue for scientists to present breakthrough research, share ideas and seek out fresh perspectives from their colleagues. Meeting attendees will also benefit from continuing education opportunities and a large supplier exposition.

AAPS is a professional scientific society of over 7,500 members employed in academia, industry, government and other public and private research institutions worldwide. The goal of AAPS is to improve human health through the development of better pharmaceuticals. AAPS members work in drug discovery, design, analysis, development, production, quality control, safety, clinical evaluation, registration, distribution, and utilization of drugs and drug delivery systems.

There is still time to make reservations to attend the AAPS Annual Meeting and Exposition. For more information about the Meeting and/or AAPS, please call the Association at (703) 548-3000.
EDITOR'S NOTE: Media covering science from trade, journal, business and consumer press are encouraged to attend the meeting. Please call Lisa Mozloom at (305) 672-4422 to pre-register and/or discuss story ideas.

American Association of Pharmaceutical Scientists

Related Drug Discovery Articles from Brightsurf:

December special issue of SLAS Discovery features 'drug discovery targeting COVID-19'
The December edition of SLAS Discovery, ''Drug Discovery Targeting COVID-19'' is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.

New cell profiling method could speed TB drug discovery
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis.

An open-access tool to accelerate drug discovery
The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules.

New macrolactone database could aid drug discovery, research
Researchers have created a free-to-use database of 14,000 known macrolactones -- large molecules used in drug development -- which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.

Discovery of a drug to rescue winter depression-like behavior
A group of animal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechanism of winter depression-like behavior and identified a drug that rescues winter depression-like behavior in medaka fish.

Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.

New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.

Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.

Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.

Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

Read More: Drug Discovery News and Drug Discovery Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to